

CLAIMS

We Claim:

- 5 1. A method of producing a gp350 protein for use in pharmaceutical compositions comprising:
 - (a) culturing host cells transformed with a DNA sequence encoding EBV gp350 protein having a deletion in the membrane spanning region and the remaining carboxy terminus, and/or a deletion of the signed sequence, said DNA sequence
10 having a mutation at one or more splice sites preventing formation of a gp220 mRNA transcript; and
 - (b) isolating the expressed homogeneous gp350 from the cell and culture medium.
- 15 2. The method of Claim 1 wherein the homogeneous gp350 is further isolated by ultrafiltration, gel filtration, ion exchange, and hydrophobic interaction chromatography.
3. The method of Claim 1 or 2 wherein the homogeneous gp350 is formulated in admixture with a pharmaceutically acceptable carrier.
- 20 4. The method of Claim 3 wherein the pharmaceutically acceptable carrier is an adjuvant/antigen presentation system.
5. The method of Claim 1 wherein said mutation at one or more splice sites is a
25 mutation in the donor splice site.
6. The method of Claim 1 wherein said mutation at one or more splice sites is a mutation in the acceptor splice site.
- 30 7. The method of Claim 5 or 6 in which at least one native nucleotide encoding serine at codon 501 of SEQ. ID. No.: 18 is replaced with a non-native nucleotide, and in which at least one native nucleotide encoding glycine at codon 698 of SEQ. ID. No.: 18 is replaced with a non-native nucleotide.

35

8. The method of Claim 6 wherein the DNA encodes a shortened version of EBV gp350 having a deletion of at least 8 amino acids in the membrane spanning region, resulting in a secreted product.
- 5 9. The method of Claim 8 wherein said mutation at one or more splice sites is a mutation in the donor splice site.
10. The method of Claim 8 wherein said mutation at one or more splice site is a mutation in the acceptor splice site.

10

15

20

25

30

35